Skip to main content
TipRanks
Go Ultimate75% OFF

UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

0 Followers
SG:8K7

UG Healthcare Corp. Ltd.

(SGX:8K7)

Select Model
Rating:64Neutral
Price Target:SGD 0.08â–²(11.94% Upside)
Action:reiterated
Date:08/29/26

The overall score is driven primarily by UG Healthcare's solid financial turnaround, marked by a return to profitability and positive cash generation. However, this fundamental strength is partially offset by a persistent long-term bearish technical trend and a moderate valuation without dividend support.

Positive Factors
Profitability RecoveryThe return to operating and net profitability indicates that the business has regained positive earnings capacity after two loss-making years. Revenue growth and improved gross margin provide evidence of recovery, although sustaining these gains will be important for durable improvement.
Negative Factors
Thin ProfitabilityAlthough the company returned to profit, very low net and operating margins leave limited protection against adverse changes in revenue or costs. The low ROE also indicates that current earnings are generating only modest returns on the capital invested in the business.

UG Healthcare Corp. Ltd. (8K7) vs. iShares MSCI Singapore ETF (EWS)

-40%-30%-20%-10%0%10%20%30%SG:8K7-30.93%EWS+3.98%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SGD 43.67M
Dividend Yield
―
Average Volume (3M)
171.96K
Price to Earnings (P/E)
19.7
Beta (1Y)
0.51
Revenue Growth
4.69%
EPS Growth
―
Country
Singapore
Employees
743
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company Description

UG Healthcare Corporation Limited, an investment holding company established in Singapore in 1989, primarily engages in the manufacturing and worldwide distribution of disposable gloves. Its business is structured across three main segments: Latex Ex...

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary

Financials highlight a post-boom turnaround with a return to top-line growth, profitability, and positive free cash flow. The low-leverage balance sheet provides stability, though profit margins remain thin.

Income Statement

65Positive

Balance Sheet

82Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue94.93M150.82M144.07M115.20M101.13M232.60M
Gross Profit3.43M42.87M34.74M25.87M1.45M84.39M
EBITDA-21.20M11.41M2.47M-3.94M-23.97M53.37M
Net Income-20.93M2.10M-3.79M-6.06M-20.73M36.80M
Balance Sheet
Total Assets215.39M240.52M232.35M226.45M230.00M288.04M
Cash, Cash Equivalents and Short-Term Investments45.13M27.41M23.29M28.00M61.74M100.22M
Total Debt28.46M40.52M47.36M43.72M31.13M17.98M
Total Liabilities44.08M70.75M76.03M65.17M48.81M52.98M
Stockholders Equity171.94M171.76M158.73M163.39M180.84M228.90M
Cash Flow
Free Cash Flow-36.98M14.97M-8.11M-20.71M-47.17M31.63M
Operating Cash Flow-34.35M17.59M-4.78M-18.16M-39.14M53.95M
Investing Cash Flow-2.63M-2.62M-3.21M-22.73M-8.03M-21.19M
Financing Cash Flow4.62M-11.20M3.24M8.36M8.70M-973.00K

UG Healthcare Corp. Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.07

Price Trends

50DMA0.08Negative
100DMA0.08Negative
200DMA0.08Negative

Market Momentum

MACD-0.00Positive
RSI43.86Neutral
STOCH32.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.86 is Neutral, neither overbought nor oversold. The STOCH value of 32.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SG:8K7 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SG:OTXSG:OTX74OutperformSGD 29.60M8.7219.60%11.45%-3.11%-21.50%
SG:8K7SG:8K764NeutralSGD 43.67M19.701.27%―4.69%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%SG:8K7SG:1J5SG:505SG:546SG:MIJSG:OTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SG:8K7 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SG:8K7UG Healthcare Corp. Ltd.0.07-0.03-30.93%
SG:1J5Hyphens Pharma International Ltd.0.340.027.81%
SG:505Asiamedic Limited0.02-0.00-11.11%
SG:546Medtecs International Corporation Ltd.0.09-0.03-25.83%
SG:MIJAlliance Healthcare Group Ltd.0.180.0763.64%
SG:OTXMedinex Ltd.0.22-0.00-1.35%

UG Healthcare Corp. Ltd. Corporate Events

UG Healthcare Shareholders Approve Key Annual General Meeting Resolutions

Nov 12, 2026

UG Healthcare Corporation held its annual general meeting, where shareholders received and adopted the audited financial statements for the financial year ended 30 June 2026. They also re-elected Lee Jun Linn as a director, approved S$120,000 in dire...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026